| [1] |
Deng L, Guo S, Liu Y, et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021 [J]. BMC Public Health, 2025, 25(1): 636.
|
| [2] |
Lucas LN, Jillella M, Cattaneo LE, et al. Investigation of bile salt hydrolase activity in human gut bacteria reveals production of conjugated secondary bile acids [J]. Nat Commun, 2026, 17(1): 3077.
|
| [3] |
Liu Y, Pei Y, Wang H, et al. Lead promoted bile acid deconjugation by modulating gut bacteria encoding bile salt hydrolase in Rana chensinensis tadpoles [J]. Environ Pollut, 2025, 373: 126187.
|
| [4] |
Kim KH, Park D, Jia B, et al. Identification and characterization of major bile acid 7α-dehydroxylating bacteria in the human gut [J]. mSystems, 2022, 7(4): e0045522.
|
| [5] |
Jalil A, Perino A, Dong Y, et al. Bile acid 7α-dehydroxylating bacteria accelerate injury-induced mucosal healing in the colon [J]. EMBO Mol Med, 2025, 17(5): 889-908.
|
| [6] |
Xu H, Fang F, Wu K, et al. Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia [J]. Microbiome, 2023, 11(1): 262.
|
| [7] |
Han B, Lv X, Liu G, et al. Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis [J]. Gut Microbes, 2023, 15(1): 2232143.
|
| [8] |
Xin Y, Ma H, Li X, et al. Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease [J]. Toxicol Appl Pharmacol, 2026, 509: 117754.
|
| [9] |
Lin X, Liang W, Li L, et al. The accumulation of gut microbiome-derived indoxyl sulfate and p-cresyl sulfate in patients with end-stage renal disease [J]. J Ren Nutr, 2022, 32(5): 578-586.
|
| [10] |
Sun DQ, Yuan FQ, Fu MZ, et al. Farnesoid X receptor activation protects against renal fibrosis via modulation of β-catenin signaling [J]. Mol Metab, 2024, 79: 101841.
|
| [11] |
Wu IW, Gao SS, Chou HC, et al. Integrative metagenomic and metabolomic analyses reveal severity-specific signatures of gut microbiota in chronic kidney disease [J]. Theranostics, 2020, 10(12): 5398-5411.
|
| [12] |
Rowe JC, Summers SC, Quimby JM, et al. Fecal bile acid dysmetabolism and reduced ursodeoxycholic acid correlate with novel microbial signatures in feline chronic kidney disease [J]. Front Microbiol, 2024, 15：1458090.
|
| [13] |
Li R, Zeng L, Xie S, et al. Targeted metabolomics study of serum bile acid profile in patients with end-stage renal disease undergoing hemodialysis [J]. PeerJ, 2019, 7: e7145.
|
| [14] |
Mansour NY, Ismail MF, Sayed NH, et al. Serum metabolomics identifies gut-derived uremic toxins and bile acid dysregulation associated with chronic kidney disease severity [J]. Sci Rep, 2026, 16(1)：12375.
|
| [15] |
Liu P, Yang J, Chen Y, et al. Alterations of gut microbiota and metabolome in early chronic kidney disease patients complicated with hyperuricemia [J]. Heliyon, 2023, 9(9): e20328.
|
| [16] |
Frazier R, Cai X, Lee J, et al. Deoxycholic acid and risks of cardiovascular events, end-stage kidney disease, and mortality in CKD: The CRIC study [J]. Kidney Med, 2022, 4(1)：100387.
|
| [17] |
Yang T, Wei B, Liu J, et al. A landscape of metabolic variation among clinical outcomes of peritoneal dialysis in end-stage renal disease [J]. Clin Chim Acta, 2024, 555: 117826.
|
| [18] |
Fu Y, Guzior DV, Okros M, et al. Balance between bile acid conjugation and hydrolysis activity can alter outcomes of gut inflammation [J]. Nat Commun, 2025, 16(1): 3434.
|
| [19] |
Koshida T, Nittono H, Takei H, et al. A comprehensive analysis of serum and urine bile acid profiles in chronic kidney disease: an exploratory study of clinical associations [J]. Nephrology (Carlton), 2026, 31(1): e70156.
|
| [20] |
Song G, Xie Y, Yi L, et al. Bile acids affect intestinal barrier function through FXR and TGR5 [J]. Front Med (Lausanne), 2025, 12: 1607899.
|
| [21] |
Zhou C, Wang Y, Li C, et al. Amelioration of colitis by a gut bacterial consortium producing anti-inflammatory secondary bile acids [J]. Microbiol Spectr, 2023, 11: e0333022.
|
| [22] |
Li B, Peng C, Wang YL, et al. The relationship between bile acids levels and the prognosis of patients with diabetes on maintenance hemodialysis: a retrospective study [J]. Ren Fail, 2023, 45(1): 2226221.
|
| [23] |
Tang CC, Tsai JP, Chen YH, et al. Impaired fasting glucose is comparable to diabetes mellitus in predicting mortality and cardiovascular events in patients undergoing peritoneal dialysis: the role of β-cell function and insulin resistance [J]. Ren Fail, 2026, 48(1): 2692758.
|
| [24] |
Jovanovich A, Isakova T, Block G, et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD [J]. Am J Kidney Dis, 2018, 71(1): 27-34.
|
| [25] |
Gao X, Ruan Y, Zhu X, et al. Deoxycholic acid promotes pyroptosis in free fatty acid-induced steatotic hepatocytes by inhibiting PINK1-mediated mitophagy [J]. Inflammation, 2022, 45(2): 639-650.
|
| [26] |
Zhang Q, Lu L, Wang J, et al. Metabolomic profiling reveals the step-wise alteration of bile acid metabolism in patients with diabetic kidney disease [J]. Nutr Diabetes, 2024, 14(1): 85.
|
| [27] |
Kang JH, Kim M, Yim M, et al. FXR/TGR5 mediates inflammasome activation and host resistance to bacterial infection [J]. Biochem Biophys Rep, 2021, 27: 101051.
|
| [28] |
Shi Y, Su W, Zhang L, et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation [J]. Front Immunol, 2021, 11: 609060.
|
| [29] |
Xiao J, Dong LW, Liu S, et al. Bile acids-mediated intracellular cholesterol transport promotes intestinal cholesterol absorption and NPC1L1 recycling [J]. Nat Commun, 2023, 14(1): 6469.
|
| [30] |
Zhou W, VanDuyne P, Zhang C, et al. Pathological bile acid concentrations in chronic cholestasis cause adipose mitochondrial defects [J]. J Hepatol Rep, 2023, 5(5): 100714.
|
| [31] |
Yang J, Tang X, Liang Z, et al. Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions [J]. Clin Mol Hepatol, 2023, 29(2): 465-481.
|
| [32] |
Gai Z, Wang T, Visentin M, et al. Lipid accumulation and chronic kidney disease [J]. Nutrients, 2019, 11(4): 722.
|
| [33] |
Kim DH, Park JS, Choi HI, et al. The role of the farnesoid X receptor in kidney health and disease: a potential therapeutic target in kidney diseases [J]. Exp Mol Med, 2023, 55(2): 304-312.
|
| [34] |
Jiang T, Wang XX, Scherzer P, et al. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy [J]. Diabetes, 2007, 56(10): 2485-2493.
|
| [35] |
Zheng X, Luo X, Zhang Y, et al. Inflammation in diabetic kidney disease is linked to gut dysbiosis and metabolite imbalance [J]. J Diabetes, 2025, 17(12): e70175.
|
| [36] |
Ha S, Yang Y, Kim JW, et al. Diminished tubule epithelial farnesoid X receptor expression exacerbates inflammation and fibrosis response in aged rat kidney [J]. J Gerontol A Biol Sci Med Sci, 2023, 78(1): 60-68.
|
| [37] |
Du C, Hu S, Li Y, et al. The NF-κB/FXR/TonEBP pathway protects renal medullary interstitial cells against hypertonic stress [J]. J Cell Mol Med, 2024, 28(10): e18409.
|
| [38] |
Guo Y, Xie G, Zhang X. Role of FXR in renal physiology and kidney diseases [J]. Int J Mol Sci, 2023, 24(3): 2408.
|
| [39] |
Guo Y, Qiao R, Xie G, et al. Activation of TGR5 increases urine concentration by inducing AQP2 and AQP3 expression in renal medullary collecting ducts [J]. Kidney Dis (Basel), 2024, 10(3): 181-192.
|
| [40] |
Guo Y, Luo T, Xie G, et al. Bile acid receptors and renal regulation of water homeostasis [J]. Front Physiol, 2023, 14: 1322288.
|
| [41] |
Lu G, Zhang S, Wang R, et al. Fecal microbiota transplantation improves bile acid malabsorption in patients with inflammatory bowel disease: results of microbiota and metabolites from two cohort studies [J]. BMC Med, 2025, 23(1): 511.
|
| [42] |
Yang Z, Tang C, Sun X, et al. Protective effects of SCFAs on organ injury and gut microbiota modulation in heat-stressed rats [J]. Ann Microbiol, 2024, 74: 6.
|
| [43] |
Wang Q, Lin H, Shen C, et al. Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling [J]. Gut Microbes, 2023, 15(2): 2274124.
|
| [44] |
Pathak P, Xie C, Nichols RG, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism [J]. Hepatology, 2018, 68(4): 1574-1588.
|
| [45] |
Canovai E, Farré R, Accarie A, et al. INT-767-A dual farnesoid-X receptor (FXR) and Takeda G protein-coupled receptor-5 (TGR5) agonist improves survival in rats and attenuates intestinal ischemia reperfusion injury [J]. Int J Mol Sci, 2023, 24(19): 14881.
|
| [46] |
Zhou H, Mu X, Hu H, et al. DHLCA alleviates diabetic kidney disease via TGR5/FXR activation and gut microbiota remodeling [J]. Drug Des Devel Ther, 2025, 19: 6469-6485.
|
| [47] |
Wang J, Zhong MY, Liu YX, et al. Branched-chain amino acids promote hepatic Cyp7a1 expression and bile acid synthesis via suppressing FGF21-ERK pathway [J]. Acta Pharmacol Sin, 2025, 46(3): 662-671.
|
| [48] |
Verzijl CRC, van de Peppel IP, Eilers RE, et al. Pharmacological inhibition of MEK1/2 signaling disrupts bile acid metabolism through loss of Shp and enhanced Cyp7a1 expression [J]. Biomed Pharmacother, 2023, 159: 114270.
|
| [49] |
Armenta-Alvarez A, Lopez-Gil S, Osuna I, et al. Removal of middle molecules and dialytic albumin loss: A cross-over study of medium cutoff and high-flux membranes with hemodialysis and hemodiafiltration [J]. Kidney360, 2023, 4(8): 1095-1102.
|
| [50] |
Whiting L, Bianchi N, Faouzi M, et al. Kinetics of small and middle molecule clearance during continuous hemodialysis [J]. Sci Rep, 2023, 13(1): 12905.
|